Human Papillomavirus (HPV) is the most common DNA virus that causes infection in the epithelial cells of skin and mucosa. The moist epithelial surfaces (squamous cells) include all areas covered by skin and/or mucosae such as the mouth interior, throat, tongue, tonsils, vagina, cervix, vulva, penis (the urethra – the opening), and anus. Contact of the areas mentioned above with a virus leads to the transmission of the virus, allowing it to transfer between epithelial cells. While it is known that sexual contacts, both conventional and oral, are the means of transferring HPV through direct skin to skin contact, other possible pathways for the transfer of virus are still poorly known.
HPV can cause cervical and other cancers, including cancer of the vulva, vagina, penis, or anus. It can also cause cancer in the back of the throat, including the base of the tongue and tonsils (called oropharyngeal cancer). Cancer often takes years, even decades, to develop after a person gets HPV. Additionally, the types of HPV, which can cause genital warts, are not the same as the types of HPV that cause cancers.
According to the National Foundation for Infectious Diseases, HPV is a group of more than 100 different viruses which spread sexually, and people can pass the virus to their partners even if they have no symptoms and even after years of their first infection.
Get FREE sample copy at:
The Human Papillomavirus (HPV) market report also covers emerging drugs, current treatment practices, Human Papillomavirus (HPV) market share of the individual therapies, current and forecasted Human Papillomavirus (HPV) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Human Papillomavirus (HPV) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Human Papillomavirus (HPV) Market Key Facts
According to the National Health and Nutrition Examination, every day in the US, about 12,000 people of ages 15–24 are infected with HPV.
According to a study conducted by McQuillan et al. (2017), the prevalence of any oral human papillomavirus (HPV) for adults aged between 18 and 69 and high-risk HPV was 7.3% and 4.0%, respectively, from 2011 to 2014.
Key Benefits of Human Papillomavirus (HPV) Market Report
Human Papillomavirus (HPV) market report provides an in-depth analysis of Human Papillomavirus (HPV) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Human Papillomavirus (HPV) market report will help in developing business strategies by understanding the Human Papillomavirus (HPV) Market trends & developments, key players and future market competition that will shape and drive the Human Papillomavirus (HPV) market in the upcoming years.
The Human Papillomavirus (HPV) market report covers Human Papillomavirus (HPV) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Human Papillomavirus (HPV) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Human Papillomavirus (HPV) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Human Papillomavirus (HPV) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Human Papillomavirus (HPV) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Human Papillomavirus (HPV) Epidemiology
The Human Papillomavirus (HPV) epidemiology section covers insights about historical and current Human Papillomavirus (HPV) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Human Papillomavirus (HPV) Drugs Uptake and Key Market Players
The Human Papillomavirus (HPV) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Human Papillomavirus (HPV) market or expected to get launched in the market during the study period. The analysis covers Human Papillomavirus (HPV) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Human Papillomavirus (HPV) market is anticipated to change in the coming years owing to the improvement in the diagnostic methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2020–2030. Various pharmaceutical companies have shifted their focus towards the development of new treatment therapies for this indication, to provide a better quality of life with minimal distress to the HPV patients.
Some of the key players in the Human Papillomavirus (HPV) market includes:
Merck & Co.
And many others.
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Human Papillomavirus (HPV) Competitive Intelligence Analysis
4. Human Papillomavirus (HPV) Market Overview at a Glance
5. Human Papillomavirus (HPV) Disease Background and Overview
6. Human Papillomavirus (HPV) Patient Journey
7. Human Papillomavirus (HPV) Epidemiology and Patient Population
8. Human Papillomavirus (HPV) Treatment Algorithm, Current Treatment, and Medical Practices
9. Human Papillomavirus (HPV) Unmet Needs
10. Key Endpoints of Human Papillomavirus (HPV) Treatment
11. Human Papillomavirus (HPV) Marketed Products
12. Human Papillomavirus (HPV) Emerging Therapies
13. Human Papillomavirus (HPV) Seven Major Market Analysis
14. Attribute Analysis
15. Human Papillomavirus (HPV) Market Outlook (7 major markets)
16. Human Papillomavirus (HPV) Access and Reimbursement Overview
17. KOL Views on the Human Papillomavirus (HPV) Market.
18. Human Papillomavirus (HPV) Market Drivers
19. Human Papillomavirus (HPV) Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Human Papillomavirus (HPV) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Human Papillomavirus (HPV) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Human Papillomavirus (HPV) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Human Papillomavirus (HPV) market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States